首页> 外文期刊>The Journal of Pharmacology and Experimental Therapeutics: Official Publication of the American Society for Pharmacology and Experimental Therapeutics >Monoamine Releasers with Varying Selectivity for Dopamine/ Norepinephrine versus Serotonin Release as Candidate 'Agonist' Medications for Cocaine Dependence: Studies in Assays of Cocaine Discrimination and Cocaine Self-Administration in Rhesus Monkey
【24h】

Monoamine Releasers with Varying Selectivity for Dopamine/ Norepinephrine versus Serotonin Release as Candidate 'Agonist' Medications for Cocaine Dependence: Studies in Assays of Cocaine Discrimination and Cocaine Self-Administration in Rhesus Monkey

机译:多巴胺/去甲肾上腺素相对于5-羟色胺释放具有不同选择性的单胺释放剂作为可卡因依赖的候选“激动剂”药物:恒河猴中可卡因鉴别和可卡因自我管理的测定方法研究

获取原文
获取原文并翻译 | 示例
       

摘要

Monoamine releasers constitute one class of drugs under investigation as candidate medications for the treatment of cocaine abuse. Promising preclinical and clinical results have been obtained with amphetamine, which has high selectivity for releasing dopamineorepinephrine versus serotonin. However, use of amphetamine as a pharmacotherapy is complicated by its high abuse potential. Recent preclinical studies suggest that nonselective monoamine releasers or serotonin-selective releasers have lower abuse liability and may warrant evaluation as alternatives to amphetamine. To address this issue, the present study evaluated the effects of five monoamine releasers in assays of cocaine discrimination and cocaine self-administration in rhesus monkeys. The releasers varied along a continuum from dopamineorepinephrine-se-lective to serotonin-selective [m-fluoroamphetamine (PAL-353), methamphetamine, m-methylamphetamine (PAL-314), 1-napthyl-2-aminopropane (PAL-287), fenfluramine]. In drug discrimination studies, rhesus monkeys were trained to discriminate saline from cocaine (0.4 mg/kg i.m.) in a two-key, food-reinforced drug discrimination procedure. Substitution for cocaine was positively associated with selectivity for dopamineorepinephrine versus serotonin release. In drug self-administration studies, rhesus monkeys responded for cocaine (0.01 and 0.032 mg/kg/injection) and food (1 -g pellets) under a second-order fixed-ratio 2 (variable-ratio 16:S) schedule. In general, monoamine releasers produced dose-dependent and sustained decreases in cocaine self-administration. However, the dopamineorepinephrine-selective releasers decreased cocaine self-administration with minimal effects on food-maintained responding, whereas the more serotonin-selective releasers produced nonselective reductions in both cocaine-and food-maintained responding. These results are consistent with the conclusion that dopamineorepinephrine-selective releasers retain cocaine-like abuse-related effects but may also be capable of producing relatively selective reductions in the reinforcing effects of cocaine.
机译:单胺释放剂构成一类正在研究中的药物,可作为治疗可卡因滥用的候选药物。苯丙胺已经获得了可喜的临床前和临床结果,苯丙胺与5-羟色胺相比对释放多巴胺/去甲肾上腺素具有高选择性。但是,由于苯丙胺具有很高的滥用潜力,因此使苯丙胺作为药物治疗变得复杂。最近的临床前研究表明,非选择性单胺释放剂或5-羟色胺选择性释放剂的滥用风险较低,可能值得评估作为苯丙胺的替代品。为了解决这个问题,本研究评估了五种单胺释放剂在恒河猴可卡因鉴别和可卡因自我给药试验中的作用。从多巴胺/去甲肾上腺素-选择剂到5-羟色胺选择性[间氟苯丙胺(PAL-353),甲基苯丙胺,间甲基苯丙胺(PAL-314),1-萘基-2-氨基丙烷(PAL-287) ),芬氟拉明]。在药物歧视研究中,恒河猴受过训练,可以通过食品强化的两个关键因素来区分可卡因中的盐水(0.4 mg / kg i.m.)。可卡因替代与多巴胺/去甲肾上腺素相对于5-羟色胺释放的选择性呈正相关。在药物自我管理研究中,恒河猴对可卡因(0.01和0.032 mg / kg /注射)和食物(1- g颗粒)的反应是按照二级固定比率2(可变比率16:S)进行的。通常,单胺释放剂可卡因的自我给药剂量依赖性且持续下降。但是,多巴胺/去甲肾上腺素选择性释放剂减少了可卡因的自我给药,对食物维持性反应的影响最小,而更多的5-羟色胺选择性释放剂使可卡因和食物维持性反应均非选择性降低。这些结果与多巴胺/去甲肾上腺素选择性释放剂保留类似可卡因的滥用相关作用但也可能在可卡因的增强作用中产生相对选择性的降低的结论是一致的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号